Andrés Orlandini *

Autor invitado por SIIC

Metanálisis de la información disponible para evaluar la utilidad de los tests de viabilidad en el proceso de indicación de revascularización en pacientes con disfunción ventricular y enfermedad coronaria

UTILIDAD DE LA VIABILIDAD MIOCÁRDICA EN PACIENTES CON DISFUNCIÓN VENTRICULAR IZQUIERDA Y ENFERMEDAD CORONARIA

La información disponible no es concluyente respecto de la utilidad del diagnóstico de viabilidad miocárdica para indicar, o no, revascularización en pacientes coronarios con disfunción ventricular. Hasta que no se realice un estudio aleatorizado con la potencia adecuada, no se deberían decidir conductas sobre la base de su presencia o ausencia.

*Andrés Orlandini
describe para SIIC los aspectos relevantes de su trabajo
MYOCARDIAL VIABILITY FOR DECISION-MAKING CONCERNING REVASCULARIZATION IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AND CORONARY ARTERY DISEASE: A META-ANALYSIS OF NON-RANDOMIZED AND RANDOMIZED STUDIES
Institución principal de la investigación
*Ecla (estudios Clínicos Latino America), Rosario, Argentina
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Rahimtoola SH. Coronary bypass surgery for chronic angina-1981. A perspective. Circulation 65:225-241, 1982.
2. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol 8:1467-1470, 1986.
3. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 30:1451-1460, 1997.
4. The Multicenter Post Infarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 309:331-336, 1983.
5. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39:1151-1158, 2002.
6. Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, O'Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. Am Heart J 146:621-627, 2003.
7. Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol 17:646-654, 2010.
8. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation 117:103-114, 2008.
9. Eitzman D, al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 20:559-565, 1992.
10. Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol 22:984-997, 1993.
11. Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 90:2687-2694, 1994.
12. Gioia G, Powers J, Heo J, Iskandrian AS. Prognostic value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardiol 75:759-762, 1995.
13. vom Dahl J, Altehoefer C, Sheehan FH, et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 38:742-748, 1997.
14. Afridi I, Grayburn PA, Panza JA, Oh JK, Zoghbi WA, Marwick TH. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 32:921-926, 1998.
15. Anselmi M, Golia G, Cicoira M, et al. Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients. Am J Cardiol 81:21G-28G, 1998.
16. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 98:II51-II56, 1998.
17. Cuocolo A, Petretta M, Nicolai E y col. Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging. Eur J Nucl Med 25:60-68, 1998.
18. Di Carli MF, Maddahi J, Rokhsar S y col. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 116:997-1004, 1998.
19. Chaudhry FA, Tauke JT, Alessandrini RS, Vardi G, Parker MA, Bonow RO. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 34:730-738, 1999.
20. Morse RW, Noe S, Caravalho J Jr, Balingit A, Taylor AJ. Rest-redistribution 201-Tl single-photon emission CT imaging for determination of myocardial viability: relationship among viability, mode of therapy, and long-term prognosis. Chest 115:1621-1626, 1999.
21. Pasquet A, Robert A, D'Hondt AM, Dion R, Melin JA, Vanoverschelde JL. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation 100:141-148, 1999.
22. Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 33:1848-1854, 1999.
23. Smart SC, Dionisopoulos PN, Knickelbine TA, Schuchard T, Sagar KB. Dobutamine-atropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction. J Am Coll Cardiol 33:512-521, 1999.
24. Shapira I, Heller I, Pines A, Topilsky M, Isakov A. The impact of myocardial viability as determined by rest-redistribution 201Tl single photon emission CT imaging and the choice of therapy on prognosis in patients with left ventricular dysfunction. J Med 31:205-214, 2000.
25. Sciagrà R, Pellegri M, Pupi A y col. Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 36:739-745, 2000.
26. Sicari R, Ripoli A, Picano E y col. VIDA (Viability Identification with Dipyridamole Administration) Study Group. The prognostic value of myocardial viability recognized by low dose dipyridamole echocardiography in patients with chronic ischaemic left ventricular dysfunction. Eur Heart J 22:837-844, 2001.
27. Zhang X, Liu XJ, Wu Q y col. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET. J Nucl Med 42:1166-1173, 2001.
28. Podio V, Spinnler MT, Bertuccio G, Carbonero C, Pelosi E, Bisi G. Prognosis of hibernating myocardium is independent of recovery of function: evidence from a routine based follow-up study. Nucl Med Commun 23:933-942, 2002.
29. Sawada SG, Lewis SJ, Foltz J y col. Usefulness of rest and low-dose dobutamine wall motion scores in predicting survival and benefit from revascularization in patients with ischemic cardiomyopathy. Am J Cardiol 89:811-816, 2002.
30. Senior R, Kaul S, Raval U, Lahiri A. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 9:454-462, 2002.
31. He ZX, Yang MF, Liu XJ y col. Association of myocardial viability on nitrate-augmented technetium-99m hexakis-2-methoxylisobutyl isonitrile myocardial tomography and intermediate-term outcome in patients with prior myocardial infarction and left ventricular dysfunction. Am J Cardiol 92:696-699, 2003.
32. Meluzín J, Cerný J, Spinarová L y col. Prognosis of patients with chronic coronary artery disease and severe left ventricular dysfunction. The importance of myocardial viability. Eur J Heart Fail 5:85-93, 2003.
33. Petrasinovic Z, Ostojic M, Beleslin B y col. Prognostic value of myocardial viability determined by a 201Tl SPECT study in patients with previous myocardial infarction and mild-to-moderate myocardial dysfunction. Nucl Med Commun 24:175-181, 2003.
34. Sicari R, Picano E, Cortigiani L y col. VIDA (Viability Identification with Dobutamine Administration) Study Group. Prognostic value of myocardial viability recognized by low-dose dobutamine echocardiography in chronic ischemic left ventricular dysfunction. Am J Cardiol 92:1263-1266, 2003.
35. Liao L, Cabell CH, Jollis JG y col. Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization. Am J Cardiol 93:1275-1279, 2004.
36. Acampa W, Petretta M, Spinelli L, Salvatore M, Cuocolo A. Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium. Eur J Nucl Med Mol Imaging 32:430-437, 2005.
37. Desideri A, Cortigiani L, Christen AI y col. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 46:1264-1269, 2005.
38. Penicka M, Tousek P, De Bruyne B y col. Myocardial positive pre-ejection velocity accurately detects presence of viable myocardium, predicts recovery of left ventricular function and bears a prognostic value after surgical revascularization. Eur Heart J 28:1366-1373, 2007.
39. Zhang X, Liu XJ, Hu S y col. Long-term survival of patients with viable and nonviable aneurysms assessed by 99mTc-MIBI SPECT and 18F-FDG PET: a comparative study of medical and surgical treatment. J Nucl Med 49:1288-1298, 2008.
40. Romero Farina G, Ferreira I, Aguadé-Bruix S, Castell-Conesa J, Igual A, Candell-Riera J. [Analysis of the number of patients needed to treat by coronary revascularisation in relation to the presence of myocardial viability in gated SPECT images: a prospective cohort study from a nuclear cardiology unit] [artículo en español. Rev Esp Med Nucl 28:6-10, 2009.
41. Cleland JG, Calvert M, Freemantle N y col. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail 13:227-233, 2011.
42. Udelson JE, Pearte CA, Kimmelstiel CD y col. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. Am Heart J 161:611-621, 2011.
43. Bonow RO, Maurer G, Lee KL y col. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 364:1617-1625, 2011.
44. van Loon R, Veen G, Baur L y col. Improved clinical outcome after invasive management of patients with recent myocardial infarction and proven myocardial viability: primary results of a randomized controlled trial (VIAMI-trial). Trials 13:1, 2012.
45. Cortigiani L, Bigi R, Sicari R. Is viability still viable after the STICH trial? Eur Heart J Cardiovasc Imaging 13:219-226, 2012.
46. Srichai MB, Jaber WA. Viability by MRI or PET would have changed the results of the STICH trial. Prog Cardiovasc Dis 55:487-493, 2013.
47. Perrone-Filardi P, Pinto FJ. Looking for myocardial viability after a STICH trial: not enough to close the door. J Nucl Med 53:349-352, 2012.

Otros artículos de Andrés Orlandini

1. O'Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, Yan H, Lee SF,
Mony P, Devanath A, Rosengren A, Lopez-Jaramillo P, Diaz R, Avezum A, Lanas F,
Yusoff K, Iqbal R, Ilow R, Mohammadifard N, Gulec S, Yusufali AH, Kruger L, Yusuf
R, Chifamba J, Kabali C, Dagenais G, Lear SA, Teo K, Yusuf S; PURE Investigators.
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N
Engl J Med 371(7):612-623, doi: 10.1056/NEJMoa1311889, Ago 2014. Erratum in: N Engl J Med 371(13):1267. PubMed PMID: 25119607, Sep 2014.
2. Dokainish H, Rajaram M, Prabhakaran D, Afzal R, Orlandini A, Staszewsky L,
Franzosi MG, Llanos J, Martinoli E, Roy A, Yusuf S, Mehta S, Lonn E.
Echocardiographic Substudy of the OASIS-6 Trial Investigators. Incremental value
of left ventricular systolic and diastolic function to determine outcome in
patients with acute ST-segment elevation myocardial infarction: the
echocardiographic substudy of the OASIS-6 trial. Echocardiography 31(5):569-578. PubMed PMID: 24702629, May 2014.
3. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S; PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310(9):959-968. doi: 10.1001/jama.2013.184182. PubMed
PMID: 24002282, Sep 2013.
4. Linetzky B, Konfino J, Castellana N, De Maio F, Bahit MC, Orlandini A, Diaz
R. Risk of cardiovascular events associated with positive serology for Chagas: a
systematic review. Int J Epidemiol 41(5):1356-1366. doi:
10.1093/ije/dys125. Review. PubMed PMID: 23045202, Oct 2012.
5. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R,
Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L,
Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in
high-income, middle-income, and low-income countries (the PURE Study): a
prospective epidemiological survey. Lancet 378(9798):1231-1243. doi:
10.1016/S0140-6736(11)61215-4. Epub 2011 Aug 26. PubMed PMID: 21872920, Oct 2011.
6. ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather
M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in
patients with atrial fibrillation. N Engl J Med 364(10):928-938. doi:
10.1056/NEJMoa1008816. PubMed PMID: 21388310, Mar 2011.
7. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon
DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748):1233-1243. doi: 10.1016/S0140-6736(10)61088-4. PubMed PMID: 20817281, Oct 2010.
8. Orlandini A, Díaz R, Wojdyla D, Pieper K, Van de Werf F, Granger CB,
Harrington RA, Boersma E, Califf RM, Armstrong P, White H, Simes J, Paolasso E.
Outcomes of patients in clinical trials with ST-segment elevation myocardial
infarction among countries with different gross national incomes. Eur Heart J
27(5):527-533. Epub 2006 Jan 12. Review. PubMed PMID: 16410369, Mar 2006.
9. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie
C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group
Investigators. Effect of glucose-insulin-potassium infusion on mortality in
patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA
randomized controlled trial. JAMA 293(4):437-446. PubMed PMID:
15671428, Ene 2005.
10. Orlandini A, Tuero E, Paolasso E, Vilamajó OG, Díaz R. Usefulness of
pharmacologic stress echocardiography in a chest pain center. Am J Cardiol 86(11):1247-1250, A6. PubMed PMID: 11090800, Dic 2000.

Para comunicarse con Andrés Orlandini mencionar a SIIC como referencia:
aorlandinimd@eclainternational

---

Acerca del trabajo completo

UTILIDAD DE LA VIABILIDAD MIOCÁRDICA EN PACIENTES CON DISFUNCIÓN VENTRICULAR IZQUIERDA Y ENFERMEDAD CORONARIA

Título original en castellano
UTILIDAD DE LA VIABILIDAD MIOCARDICA EN PACIENTES DISFUNCION VENTRICULAR IZQUIERDA Y ENFERMEDAD CORONARIA. META-ANALISIS DE ESTUDIOS NO RANDOMIZADOS Y RANDOMIZADOS.

Autores
Andrés Orlandini¹, Noelia Castellana², Noelia Castellana³, Noelia Castellana⁴, Andrea Pascual⁵, Andrea Pascual⁶, Fernando Botto⁷, Fernando Botto⁸, M. Cecilia Bahit⁹, Andrea Pascual¹⁰, Carolina Chacon¹¹, M. Cecilia Bahit¹², Fernando Botto¹³, Maria Luz Diaz¹⁴, Carolina Chacon¹⁵, M. Cecilia Bahit¹⁶, Rafael Diaz¹⁷, Maria Luz Diaz¹⁸, Carolina Chacon¹⁹, Rafael Diaz²⁰, Maria Luz Diaz²¹, Rafael Diaz²²
1 Médico, Ecla (estudios Clínicos Latino America), Rosario, Argentina, Director
2 Estadística, Ecla
3 Estadística, Ecla
4 Estadística, Ecla
5 Ingeniera, Ecla
6 Ingeniera, Ecla
7 Médico, Ecla
8 Médico, Ecla
9 Médica
10 Ingeniera, Ecla
11 Médica, Ecla
12 Médica
13 Médico, Ecla
14 Médica, Ecla
15 Médica, Ecla
16 Médica
17 Médico, Ecla, Director
18 Médica, Ecla
19 Médica, Ecla
20 Médico, Ecla, Director
21 Médica, Ecla
22 Médico, Ecla, Director

Acceso a la fuente original
International Journal of Cardiology
http://www.ijc.elsevier.com

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades